
Opinion|Videos|December 29, 2023
Clinical Data on the Approved JAK Inhibitors for Treatment of Myelofibrosis
Author(s)Christine Cooper, RN, BSN, Aaron Gerds, MD, MS
An expert discusses the four FDA-approved JAK inhibitors for myelofibrosis - ruxolitinib, fedratinib, pacritinib, and momelotinib.
Advertisement
Episodes in this series

Advertisement
Related to this article

Patients with PD-L1-negative non-small cell lung cancer experienced longer progression-free survival with sac-TMT plus Keytruda compared with chemotherapy plus Keytruda in a phase 3 trial.

For National Hospice and Palliative Care Month, answers to common questions about how palliative care differs from hospice, who qualifies, what Medicare covers and how to find a program.

A nurse practitioner discusses how an app provides information on cancer treatments, potential side effects and preparing for medical appointments.

A breast cancer survivor shares how cancer turned gratitude into an everyday practice and why it's OK when the holidays bring both joy and grief this year.

Final KEYNOTE-564 data show Keytruda after kidney cancer surgery lowered the risk of death by 30%. Dr. Toni Choueiri explains what it means for patients.

HealthCare.gov open enrollment runs Nov. 1, 2026, to Jan. 15, 2027, and the 2027 out-of-pocket ceiling rises to $12,000. Here's what people with cancer should check before picking a plan.

After nearly a year of chemotherapy, a patient with stage 4 pancreatic cancer describes daily life and side effects on Rasonque (daraxonrasib).
Advertisement
Advertisement
Trending on CURE
1
Why a Patient With Pancreatic Cancer Moved From Chemotherapy to Rasonque
2
Keytruda After Kidney Cancer Surgery Lowers Risk of Death by 30%
3
Sac-TMT Plus Keytruda Improves Outcomes in PD-L1-Negative Lung Cancer
4
ACA Open Enrollment 2027: What Patients With Cancer Should Check
5

